Recombinant human leukemia inhibitory factor is mitogenic for human bone-derived osteoblast-like cells.
Recombinant human leukemia inhibitory factor is mitogenic for human bone-derived osteoblast-like cells.
复制标题
DOI：
10.1006/bbrc.1994.1217
复制
发表时间：
1994-02
影响因子：
3.1
通讯作者：
D. Evans;B. Gerber;J. Feyen
中科院分区：
文献类型：
--
作者：
D. Evans;B. Gerber;J. Feyen
重组人白血病抑制因子（rhLIF）对人骨源性成骨样细胞的体外促分裂作用以前列腺素E2非依赖性方式刺激[3 H]-胸苷掺入DNA。rhLIF对基础骨钙素合成和1，25（OH）2D 3诱导的碱性磷酸酶（AP）活性均无影响。用rhLIF处理后，放射性标记的细胞核与AP共定位，表明rhLIF的促有丝分裂作用发生在成骨谱系的细胞上。因此，在人骨表面局部产生的LIF可能作为成骨细胞谱系祖细胞的潜在自分泌/旁分泌促分裂原，因此可能与LIF的已知骨形成特性相关。
Recombinant human leukemia inhibitory factor (rhLIF) is mitogenic for human bone-derived osteoblast-like cells in vitro. [3H]-thymidine incorporation into DNA was stimulated dose-dependently in a prostaglandin E2-independent manner. rhLIF exerted no effect on either the basal or 1,25(OH)2D3-induced synthesis of osteocalcin or alkaline phosphatase (AP) activity. Following treatment with rhLIF, radiolabelled cell nuclei were co-localized with AP, indicating that the mitogenic effect of rhLIF occurs on cells of the osteogenic lineage. Local generation of LIF at the human bone surface may therefore serve as a potential autocrine/paracrine mitogen for progenitor cells of the osteoblastic lineage and so could correlate with the known bone forming properties of LIF.